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ABSTRACT
The tumor suppressor p53 responds to a wide var-
iety of cellular stress signals. Among potential regu-
latory pathways, post-translational modifications
such as acetylation by CBP/p300 and PCAF have
been suggested for modulation of p53 activity.
However, exactly how p53 acetylation is modulated
remains poorly understood. Here, we found that
SET/TAF-Ib inhibited p300- and PCAF-mediated
p53 acetylation in an INHAT (inhibitor of histone
acetyltransferase) domain-dependent manner.
SET/TAF-Ib interacted with p53 and repressed tran-
scription of p53 target genes. Consequently, SET/
TAF-Ib blocked both p53-mediated cell cycle arrest
and apoptosis in response to cellular stress. Using
different apoptosis analyses, including FACS,
TUNEL and BrdU incorporation assays, we also
found that SET/TAF-Ib induced cellular proliferation
via inhibition of p53 acetylation. Furthermore, we
observed that apoptotic Drosophila eye phenotype
induced by either dp53 overexpression or UV irradi-
ation was rescued by expression of dSet. Inhibition
of dp53 acetylation by dSet was observed in both
cases. Our findings provide new insights into the
regulation of stress-induced p53 activation by
HAT-inhibiting histone chaperone SET/TAF-Ib.
INTRODUCTION
The tumor suppressor protein (p53) is induced in response
to a wide variety of stress signals and regulates the tran-
scription of genes responsible for many cellular processes,
including cell cycle regulation and apoptosis. A series of
post-translational modiﬁcations are involved in p53
responses to different stimuli, and some of these modiﬁca-
tions are known to inﬂuence regulation of p53 activity.
Among the many post-translational modiﬁcations of p53,
acetylationhasbeenoneofthemostextensivelystudied(1).
The histone acetyltransferases p300/CBP (CREB-
binding protein) and PCAF (p300/CBP-associated
factor) acetylate p53 and enhance its transcriptional
activity (2–6). The acetylation of p53 is further expanded
by other acetyltransferases such as hMOF and TIP60 at
lysine 120 (K120) in response to DNA damage (7). p53
can be acetylated by p300/CBP at multiple lysine residues
(K164, 370, 372, 373, 381, 382 and 386) and by PCAF at
K320. Earlier studies using mice with seven (7KR) or six
C-terminal lysines changed to arginine (6KR) displayed
only minor effects in p53-mediated activity (8–10).
However, loss of acetylation at all eight lysines (8KR)
completely abolished p53-mediated stress response, sug-
gesting an indispensable role for acetylation in p53
activation (11).
We previously identiﬁed SET/TAF-Ib and pp32 as
subunits of the INHAT (inhibitor of histone acetyl-
transferase) complex with ‘histone masking’ activity; that
is binding of these proteins to histones prevents acetyl-
ation by p300/CBP and PCAF (12). Additional studies
revealed that INHAT binds the N-termini of histone tails,
and modiﬁcations within histone tails affect INHAT
binding (13). SET/TAF-Ib speciﬁcally binds to unacety-
lated, hypo-acetylated histones and not to hyper-
acetylated ones, which implies a novel in vivo function in
transcriptional repression (14).
INHAT is a multiprotein complex composed of highly
acidic domain-containing proteins, SET/TAF-Ib, TAF-Ia
and pp32 (12). Initial biochemical studies revealed that
SET/TAF-Ib can promote adenoviral DNA replication,
nucleosome assembly and transcription (15). Both the
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indicate that it has the potential to regulate and integrate
cytoplasmic and nuclear signaling pathways, including
mRNA transport and stability (16). As multitasking pro-
teins, SET/TAF-Ib and pp32 have been reported to be
negative and positive regulators of caspase-independent
and -dependent apoptotic signaling, respectively (17–19).
In fact, SET/TAF-Ib was originally identiﬁed as a trans-
located gene in acute undifferentiated leukemia, which
further supports its oncogenic activity (15,20,21).
Here, we show that SET/TAF-Ib inhibits p53 acetyl-
ation and modulates its key effects, including cell cycle
arrest and apoptosis induction. In our in vivo analysis using
UAS-dSet and dp53 in Drosophila, we provide evidence
that dSet inhibits acetylation of Drosophila dp53 and
negatively regulates dp53-mediated apoptosis.
MATERIALS AND METHODS
Plasmids
The CMX-SET/TAF-Ib plasmid was used as described
previously (12). p53 and p53 mutants were inserted into
pGEX-4T1 bacterial expression vector (Amersham
Biosciences) to construct glutathione S-transferase (GST)
fusion proteins. In order to construct the mammalian ex-
pression vectors, we employed modiﬁed pcDNA6-HA-
myc-his (Invitrogen) and used pGEX-4T1-p53 to create
the HA, myc and his-tagged p53 and p53 mutants.
sh-RNA against human SET/TAF-Ib (RHS4533) was
purchased from Openbiosystems.
Antibodies
Antibodies against p53 (DO-1) (Santa Cruz Biotechnology),
acetyl-p53 (K320) (Millipore), acetyl-p53 (K373/382)
(Millipore), acetyl lysine (Ac-K) (Santa Cruz
Biotechnology), SET/TAF-Ib (Santa Cruz Biotechnology),
anti-myc (Santa Cruz Biotechnology) and b-actin (Santa
Cruz Biotechnology) were employed for immunoblot,
immunoprecipitation and chromatin immunoprecipitation
(ChIP) analyses.
In vitro INHAT assay
INHAT assays were performed by incubating 20–30pmol
of puriﬁed GST-SET/TAF-Ib with 1mg of GST-p53 in
HAT buffer (12) for 15min on ice. Following
pre-incubation, 1pmol of PCAF or 1mg of p300 along
with
14[C]-acetyl CoA (50mCi/ml, Perkin Elmer) or
100mM acetyl coenzyme A were added for 2h at 30 C.
Reaction products were separated by SDS–PAGE and
analyzed by a phosphorimager. For scintillation counting,
p53-K320 peptides [PQPKKKPLDG] and p53-K383
peptides [SRRKKLMFKT] were synthesized based on
the N-terminal amino acid sequences of histone H3
(Peptron). Peptides were ﬁltered using p81 ﬁlter paper
(Upstate Biotechnology) and washed three times with
cold 10% TCA and 70% ethanol for 5min at RT. The
ﬁlters were then allowed to air dry, followed by the
addition of 1ml of Ultima Gold (Perkin Elmer).
14[C]-
acetyl CoA was quantiﬁed using a scintillation counter.
Liquid chromatography–mass spectrometry
Synthetic peptides (p53-K320 or p53-K383) (100mM) were
used as substrates in the INHAT assay with SET/TAF-Ib
and PCAF or p300. The reaction was stopped with 10%
TCA precipitation for 10min at 4 C. After removing the
precipitates by centrifugation, the supernatants were
retrieved and acetylated peptides in the supernatants
analyzed by liquid chromatography–mass spectrometry
(LC–MS) at the Korea Basic Science Institute. The
eluted peptides were separated on a Luna column (C18
PepMap 100, 150 1mm 5 micron) with a linear gradient
(A: 5% ACN, 0.1% formic acid; B: 95% ACN, 0.1%
formic acid) at a ﬂow rate of 50ml/min. Typically, 5mlo f
sample was injected. Mass spectrometry was performed on
a linear ion trap mass spectrometer (LCQ DECA XP,
Thermo Finnigan) coupled to a nano-LC system
(NANOSPACE SI-2, Shiseido). The MS scan range was
160–2000m/z.
Immunoprecipitation
For the p53 and SET/TAF-Ib interaction assays, trans-
fected cells were lysed in RIPA lysis buffer and immuno-
precipitated with anti-p53, anti-SET/TAF-Ib and
anti-c-myc antibodies overnight at 4 C. Protein A/G
agarose beads (GenDEPOT) were added for 1h with rota-
tion at 4 C. The bound proteins were analyzed by
immunoblotting with anti-p53 and anti-SET/TAF-Ib
antibodies.
In vitro transcription and translation reactions
For in vitro transcription and translation, the [
35S]-labeled
SET/TAF-Ib proteins were constructed with a coupled
transcription and translation (TNT) system (Promega).
In brief, 1mg of DNA was directly added to TNT rabbit
reticulocyte lysates and then allowed to react for 2h at
30 C. The reaction mixtures were utilized in a GST
pull-down assay using GST-p53 and GST-p53 deletion
mutants. The precipitated proteins were separated via
10% SDS–PAGE and visualized by autoradiography.
Transfection assay
Transfection assay was conducted using the p21 promoter
reporter along with CMX-SET/TAF-Ib, HA-p53, ﬂag-
PCAF, SET/TAF-Ib3 and sh-SET/TAF-Ibs. The
quantity of DNA in each transfection was kept constant
via the addition of CMX. U2OS, 293 and H1299 cells were
transfected with the p21 promoter reporter (100ng),
HA-p53, ﬂag-PCAF (100ng), CMX-SET/TAF-Ib (100,
200ng), SET/TAF-Ib3 (200ng), sh-SET/TAF-Ibs
(200ng), NAP-1 (200ng) and si-HDAC1 (200nM). At
24h after transfection, the cells were treated with
330nM TSA or 5mM nicotinamide (Sigma). Cells were
then harvested and assayed for luciferase activity using a
luciferase assay system (Promega). Each value is expressed
as the mean of six replicates of a single assay, and the
results were conﬁrmed by performing at least three
repetitions.
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U2OS and H1299 cells were transfected with p53, SET/
TAF-Ib and sh-SET/TAF-Ib. Total RNAs were then iso-
lated using RNAiso Plus (TaKaRa). cDNA was generated
with 1mg of RNA using oligodTs and reverse transcriptase
(RTase) (Enzynomics). Primers and PCR conditions have
been described previously (22).
Chromatin immunoprecipitation
U2OS and H1299 cells were transfected with 4mg of DNA
and harvested after 48h. Cells were then cross-linked with
1% formaldehyde in medium for 10min at 37 C, followed
by the addition of 125mM glycine for 5min at RT, after
which they were scraped into SDS lysis buffer. The cells
were further sonicated and diluted for immunopre-
cipitation with antibodies as indicated. The resulting
immunoprecipitates were eluted and reverse cross-linked.
DNA fragments were puriﬁed and PCR ampliﬁed for
quantiﬁcation. Anti-p53, anti-p300 and anti-PCAF were
employed for immunoprecipitation. The primer sequences
were as follows: p21 (forward, 50-GTG GCT CTG ATT
GGC TTT CTG-30; reverse, 50-CTG AAA ACA GGC
AGC CCA AG-30) and PUMA (forward, 50-GTA CAT




Two thousand cells were seeded (48-well plates) 24h prior
to transfection with p53, SET/TAF-Ib and sh-SET/
TAF-Ib. After 0–4 days of incubation at 37 C, 20mlo f
MTT (1mg/ml) was added and incubated for 4h at
37 C, followed by aspiration of the medium and
addition of 200ml of dimethyl sulfoxide (DMSO). The
OD was determined using a spectrophotometer at a wave-
length of 570nm.
Flow cytometry
Forty-eight hours after transfection, cells were ﬁxed in
70% ethanol for 24h, treated with RNase (20mg/ml)
and stained with propidium iodide. Cell cycle proﬁles
were analyzed by FACS Calibur (Becton Dickinson).
BrdU incorporation assay
The assay was performed according to the manufacturer’s
instructions (Roche Diagnostics). U2OS and H1299 cells
were cultured on 48-well plates and transfected with p53,
SET/TAF-Ib and sh-SET/TAF-Ib. After 72h, cells were
incubated in medium containing BrdU for 2h, after which
the absorbance was measured at 370nm (reference wave-
length : 475nm).
Apoptosis by TUNEL assay
Apoptosis was detected by TUNEL (TdT-mediated dUTP
nick end labeling) assay (In Situ Cell Death Detection Kit,
Roche). Brieﬂy, H1299 cells were seeded in chamber slides
and transfected with p53, SET/TAF-Ib SET/TAF-Ib3
and sh-SET/TAF-Ib. The cells were then ﬁxed with 4%
paraformaldehyde for 1h at RT, followed by incubation
for 1h at 37 C with terminal deoxynucleotidyl transferase
enzyme (TdT) in reaction buffer. The cells were then
incubated with AP (alkaline phosphatase)-conjugated
antibody for 1h at 37 C, and the reaction was developed
with NBT/BCIP substrate for 2h at RT.
Drosophila culture and stocks
Drosophila melanogaster was cultured at 25 C by following
the standard method. Wild-type Oregon-R, w-, GMR-gal4
and UAS-dp53 were obtained from the Bloomington
Stock Center (Bloomington, USA). Drosophila Set (dSet)
810bp coding sequences were subcloned into pUAST
vector to generate the pUAS-dSet construct. UAS-dSet
transgenic ﬂy was obtained by P-element-mediated
germ-line transformation (23). To express these UAS
lines, the UAS/gal4 system was used (24). Detailed infor-
mation is provided in the Supplementary Data.
RESULTS
Inhibition of p53 acetylation by SET/TAF-Ib
To understand the regulation of p53 acetylation through
the HAT inhibitory activity of SET/TAF-Ib, we ﬁrst tested
whether or not SET/TAF-Ib can inhibit p300- and
PCAF-mediated p53 acetylation using HAT assays both
in vitro and in vivo. Both recombinant PCAF- and
p300-acetylated p53, but the addition of increasing
amounts of SET/TAF-Ib inhibited this (Figure 1A and
B). Using C-terminal INHAT domain-deleted mutant
SET/TAF-Ib3, we veriﬁed that INHAT domain was re-
sponsible for the inhibition of p300- and PCAF-mediated
p53 acetylation (Figure 1A and B). Coomassie stain-
ing revealed consistent p53 levels in the INHAT assay.
Immunoblotting performed on the proteins after in vitro
HAT assay showed strong inhibition of both p300-
and PCAF-mediated p53 acetylation by the INHAT
domain of SET/TAF-Ib, but not by SET/TAF-Ib3
(Figure 1C and D). Recent studies have shown that p53
can be acetylated by p300/CBP at multiple C-terminal
lysine residues, including K373 and K382 (2,25). In
addition, p53 can be acetylated by PCAF at K320 (4). To
further elucidate whether or not SET/TAF-Ib can inhibit
speciﬁc p53 lysine targets of p300 and PCAF, we used
antibodies speciﬁc for acetyl-p53 (K320) and acetyl-p53
(K373/382) residues. Addition of SET/TAF-Ib clearly
decreased the acetylation of p53-K320 and p53-K373/382
residues (Figure 1C and D). As expected, the effects of
SET/TAF-b3 were minimal (Figure 1C and D). To
further conﬁrm the p53 acetylation inhibitory activity of
SET/TAF-Ib, we conducted HAT assay using p53
peptides containing two independent acetylation target
lysine residues and measured acetylation levels by scintilla-
tion counting. HAT activities of PCAF and p300 as well as
INHATactivityofSET/TAF-Ibweretestedﬁrstusingcore
histones (Supplementary Figure S1A and S1B). Incubation
of p53 (K320) and p53 (K382) peptides with PCAF and
p300, respectively, induced strong acetylation. Addition
of SET/TAF-Ib but not SET/TAF-Ib3 signiﬁcantly
reduced acetylation levels, clearly conﬁrming the INHAT
activity of SET/TAF-Ib toward non-histone protein p53
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demonstrated strong inhibitory activity of SET/TAF-Ib
but not SET/TAF-Ib3 toward both PCAF- and
p300-mediated p53 acetylation (Figure 1G and H). The
inhibition of endogenous p53 acetylation by SET/TAF-Ib
was further conﬁrmed in vivo by immunoprecipitation (IP)
of p53. In transient co-transfection assays in p53-positive
HCT116 cells, a high level of p53 acetylation was observed
(Figure 1I). As expected, overexpression of SET/TAF-Ib
induced a 4-fold decrease in p53 acetylation. The observa-
tion that overexpression of SET/TAF-Ib3 decreased the
acetylation level of p53 could suggest that inhibition of p53
acetylation is mostlydependent on theacidic C-terminus of
SET/TAF-Ib (Figure 1I).
SET/TAF-Ib inhibits stress-induced p53 acetylation
Cellular stresses, such as treatment with DNA-damaging
agents, induce p53 acetylation and activity. To study the
effects of SET/TAF-Ib on stress-induced p53 acetylation
in vivo, thelevels of acetylated p53 weremonitored usingan
acetylated lysine antibody and speciﬁc acetyl-p53
antibodies. Doxorubicin, a DNA-damaging agent was
used to impose cellular stress. Importantly, we veriﬁed that
SET/TAF-Ib protein levels were not altered under these
conditions (Figure 2A and B; Supplementary Figure
S3B). Additionally, p53 protein levels were not changed
by either SET/TAF-Ib or SET/TAF-Ib-3 in the pres-
ence or absence of stress induction (Supplementary
Figure S3A). In exogenous p53-expressing H1299, U2OS
and 293 cells, treatment with doxorubicin resulted in
increased p53 acetylation. When SET/TAF-Ib was
knocked down by two sh-SET/TAF-Ib RNAs, further in-
creases in p53 acetylation were induced, which indicates
that endogenous SET/TAF-Ib inhibited stress-induced
p53 acetylation (Figure 2A and B; Supplementary Figure
S3B). These two independent sh-SET/TAF-Ib RNAs also
successfully downregulated SET/TAF-Ib, as conﬁrmed by
RT–PCRandwesternblotting(SupplementaryFigureS2A
and S2B).
Figure 1. SET/TAF-Ib inhibits PCAF- and p300-mediated p53 acetylation. (A and B) Acetylation assays of p53 with PCAF and p300 were
performed with increasing concentrations of SET/TAF-Ib or SET/TAF-Ib-3. Autoradiogram of INHAT assay using recombinant PCAF (A) or
p300 (B) with SET/TAF-Ib and SET/TAF-Ib3 on GST-p53 (top) followed by coomassie staining (bottom). Numbers below phosphorimage
represent quantiﬁcation of p53 acetylation. (C and D) Western blot analysis of in vitro p53-acetylation assay with PCAF (C) or p300 (D),
GST-p53, GST-SET/TAF-Ib or GST-SET/TAF-Ib3 using anti-acetyl-p53 (K320) or anti-acetyl-p53 (K373/382) and anti-acetyl lysine. The levels
of GST-SET/TAF-Ib and SET/TAF-Ib-3 are shown in the bottom panel by coomassie staining. (E and F) p53 peptides (p53-K320 and p53-K382)
were used as substrates in the INHAT assay with PCAF (E) or p300 (F) with GST-SET/TAF-Ib or SET/TAF-Ib-3. Acetylation levels were
quantiﬁed via ﬁlter binding assay and represented as raw counts per minute (cpm) incorporated.
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(continued)SET/TAF-Ib interacts with p53 via INHAT domain
To determine whether or not p53 directly interacts with
SET/TAF-Ib, we conducted in vitro binding assays with
puriﬁed GST-SET/TAF-Ib and His-p53 protein.
Compared to control GST, p53 protein strongly bound
to immobilized GST-SET/TAF-Ib, and this interaction
was strictly dependent on the INHAT domain of SET/
TAF-Ib (Figure 3A). In vivo interactions between p53
and SET/TAF-Ib but not SET/TAF-Ib3 were conﬁrmed
Figure 1. Continued
(G and H) p53 peptides were incubated with PCAF (G) or p300 (H) with GST-SET/TAF-Ib, and the modiﬁed peptides were analyzed via LC–MS
spectrometry. (I) HCT116 cells were transfected with various plasmids, as indicated, and p53 immunoprecipitates were subjected to western blotting
using anti-acetyl lysine. Quantiﬁcation of acetylated p53 band intensities is shown below. The amounts of immunoprecipitated p53 and transfected
SET/TAF-Ib proteins were determined by western blotting and shown in the lower panels.
Figure 2. SET/TAF-Ib inhibits p53 acetylation under stress conditions. (A and B) Western blot analysis of whole cell extracts of H1299 (A) and
U2OS cells (B) transfected with p53 alone or co-transfected with sh-CTL and sh-SET/TAF-Ib #1 or #2, followed by immunoblotting against
anti-acetyl-p53(K373/382), anti-acetyl-p53(K320), anti-acetyl lysine, anti-p53, anti-SET/TAF-Ib or anti-b-actin antibodies. Cells were either untreated
or treated with 1mM doxorubicin.
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p53 and SET/TAF-Ib antibodies (Figure 3B). To identify
the p53 domain involved in interaction, we performed an
in vivo IP interaction assay using p53 deletion mutants.
The results indicate that the C-terminus region of p53,
which contains important acetylation target residues,
was responsible for the interaction with SET/TAF-Ib,
even though the interaction was less strong than that of
wild-type p53 (Figure 3C). Additionally, in vitro transcrip-
tion and translation of SET/TAF-Ib were retained on
a GST-p53 and p53 (294–393) glutathione sepharose
afﬁnity matrix similar to the pattern in Figure 3C, which
suggests the participation of an additional domain besides
the p53 C-terminal domain in the full interaction between
p53 and SET/TAF-Ib (Figure 3D). When we compared
the SET/TAF-Ib and p53 interaction under stress and
Figure 3. SET/TAF-Ib interacts with p53 both in vitro and in vivo.( A) Interaction assay of input and eluates from indicated GST-SET/TAF-Ib and
deletion mutants incubated with p53 and immunoblotted with anti-p53. INHAT domain of SET/TAF-Ib is shown as a black box. The amounts of
His-p53, GST-SET/TAF-Ib and deletion mutants used in the assay were determined by coomassie staining. (B) Western blot analysis of SET/TAF-Ib
immunoprecipitates from 293 cells expressing HA-p53, SET/TAF-Ib and SET/TAF-Ib3 was performed with anti-p53 antibody. The amounts of
immunoprecipitated SET/TAF-Ib and SET/TAF-Ib-3 were determined by western blotting (lower panel). (C) 293 cells were transfected with
indicated myc-p53 and myc-p53 deletion mutants, immunoprecipitated with anti-myc and immunoblotted with anti-SET/TAF-Ib antibodies. The
expression levels of myc-p53 protein were determined by western blotting (lower panel). (D) In vitro transcribed and translated SET/TAF-Ib were
incubated with GST, GST-p53 or GST-p53 deletion mutants. The levels of full-length p53 and p53 deletion mutants were determined by coomassie
staining. (E) Western blot analysis of the input and p53 immunoprecipitates from U2OS cells with anti-SET/TAF-Ib antibodies. Cells were either
untreated or treated with 1mM doxorubicin. The amounts of immunoprecipitated p53 proteins were determined by western blotting (bottom).
Quantiﬁcation of acetylated p53 band intensities is shown below.
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action under stress condition was observed (Figure 3E).
It may be possible that a minor fraction of p53 associates
with SET/TAF-Ib before stress and full interaction is
induced upon stress induction.
From these results, we can conclude that SET/TAF-Ib
targets p53 by speciﬁcally associating with its hypo-
acetylated state, inhibits p53 acetylation via substrate
masking from HATs, and possibly induces a transcrip-
tional repressive state in p53 target genes.
Inhibition of p53-mediated transcriptional activation
by SET/TAF-Ib
To evaluate the effect of SET/TAF-Ib on p53-mediated
transcriptional activation, we co-transfected p53, PCAF
and SET/TAF-Ib expression vectors along with the syn-
thetic minimal p21 reporter into different cell lines. In
reporter assays performed in exogenous p53-expressing
H1299 cell lines, SET/TAF-Ib reduced the activation of
p21 reporter mediated by exogenous p53, showing that the
regulatory activity of SET/TAF-Ib was p53 dependent
(Figure 4A). SET/TAF-Ib-mediated repression was effect-
ive with endogenous PCAF and further evidenced
with exogenous PCAF (Supplementary Figure S4A).
Knockdown of SET/TAF-Ib by two different sh-RNAs
slightly upregulated endogenous p53-dependent p21 tran-
scription and signiﬁcantly activated exogenous p53-
mediated p21 transcription (Figure 4A and Supplementary
Figure S4B–D). Endogenous p53-mediated transactivation
was signiﬁcantly repressed by the addition of exogenous
SET/TAF-Ib (Supplementary Figure S4E). Again, SET/
TAF-Ib3 had almost no effect on the transactivational
activities of p53, which indicates that the physical inter-
action of p53 with the INHAT domain was crucial for
SET/TAF-Ib-mediated repression (Figure 4A and B;
Supplementary Figure S4E). As a member of the histone
chaperone nucleosome assembly protein (NAP) family,
SET/TAF-Ib shares sequence homology including a
highly acidic domain with NAP-1 protein. To rule out
the possibility that the observed effect of SET/TAF-Ib
on p53 was due to the presence of an acidic domain,
we performed the same p21 reporter assays with NAP-1.
As expected and previously reported, NAP-1 slightly
upregulated p21 reporter activity mediated by p53
(Figure 4B). Indeed, it is known that NAP-1 activates
p53-mediated transcription through direct interaction
with p53 and p300 (26–28).
SET/TAF-Ib represses transcription of p53 target genes
To understand the functional effects of SET/TAF-
Ib-mediated inhibition on p53 acetylation, we analyzed
the effects of SET/TAF-Ib expression on endogenous p53
targetgenesinU2OScells.Real-timePCRanalysesshowed
that overexpression of SET/TAF-Ib signiﬁcantly
downregulated stress-induced expression of p53 target
genes, including p21, Bax and PIG3 (Figure 5A). More
importantly, knockdown of endogenous SET/TAF-Ib by
two different sh-RNAs further induced expression of the
same target genes, which conﬁrms the effect of endogenous
SET/TAF-Ib on p53 target genes (Figure 5A). To deter-
mine whether or not the regulation of p53 target genes by
SET/TAF-Ib is p53 dependent, we performed the same
real-time PCR analysis in exogenous p53-expressing
H1299 cells. Again, the expression of p21, Bax and PIG3
was reduced by SET/TAF-Ib and induced by different
sh-SET/TAF-Ibs only in the presence of exogenous p53,
which demonstrates the p53-dependent regulatory effects
of SET/TAF-Ib (Supplementary Figure S5A and data not
shown). Having established the regulation of p53 target
genes by SET/TAF-Ib, we next determined whether or
not SET/TAF-Ib modulates the recruitment of p53 to
target chromatins in vivo by ChIP assays combined with
Figure 4. SET/TAF-Ib inhibits p53-mediated transcriptional activation. (A) H1299 cells were transfected with p53, SET/TAF-Ib, SET/TAF-Ib3,
sh-CTL, sh-SET/TAF-Ibs and PCAF. (B) 293 cells were transfected with the p21 promoter-luc construct along with p53, SET/
TAF-Ib, SET/TAF-Ib3 and NAP-1 in the presence or absence of PCAF. Data in A and B are presented as mean SD; n=4. *P<0.05 and
***P<0.001.
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was signiﬁcantly reduced by SET/TAF-Ib in doxorubicin-
treated U2OS cells and exogenous p53-expressing H1299
cells (Figure 5B and Supplementary Figure S5B). Notably,
further increases in p53 recruitment were detected upon
SET/TAF-Ib knockdown, demonstrating that endogenous
SET/TAF-Ib inhibited the association of p53 with the p21
promoter (Figure 5B and Supplementary Figure S5B). The
effects of SET/TAF-Ib on p53 recruitment to the PUMA
promoter were further investigated in U2OS cells and ex-
ogenous p53-expressing H1299 cells (Figure 5C and
Supplementary Figure S5C). Again, ChIP analysis
Figure 5. SET/TAF-Ib represses transcription of p53-target genes. (A) Real-time PCR analysis of p53-target genes p21, Bax and PIG3 in the
presence of SET/TAF-Ib, sh-CTL and sh-SET/TAF-Ib #1 or #2 upon doxorubicin treatment in U2OS cells. (B and C) ChIP assay of SET/
TAF-Ib and sh-SET/TAF-Ib #1 or #2-transfected U2OS cells for measurement of p53 recruitment to the p21 (B) and PUMA promoters
(C) upon doxorubicin treatment. Recruitment of p53 to the p21 or PUMA promoter was normalized to input. The data are averages of
three independent experiments, and the error bars represent SD. **P<0.01 and ***P<0.001 compared with untreated control. (D and E)
Recruitment of p300 and PCAF to the p21 promoter region was analyzed via ChIP assay and real-time PCR using SET/TAF-Ib and sh-SET/
TAF-Ib #1 or #2-transfected U2OS cells upon doxorubicin treatment.
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(continued)combined with real-time PCR showed that SET/TAF-Ib
signiﬁcantly downregulated doxorubicin-induced p53
recruitment to the PUMA promoter, and different
sh-SET/TAFIbs resulted in elevated levels of recruitment
(Figure 5C and Supplementary Figure S5C). These results
suggest that SET/TAF-Ib functioned effectively in cellular
stress-induced p53 activation by regulating the recruitment
of p53 to target promoters. In contrast, transfection of
SET/TAF-Ib into exogenous p53-expressing H1299 cells
resulted in no detectable changes in p53 recruitment to
the p21 and PUMA promoters (Supplementary Figure
S5D and S5E). We further analyzed p300 and PCAF re-
cruitment to the p21 and PUMA promoters using real-time
PCR and ChIP analyses. There were no noticeable changes
in p300 and PCAF recruitment to either promoter under
both stress and non-stress conditions. However, sh-SET/
TAF-Ib signiﬁcantly increased p300/PCAF recruitment
to both promoters in the presence of doxorubicin, conﬁrm-
ing repression of transcription by SET/TAF-Ib (Figure 5D
and E).
Negative regulation of p53-mediated apoptosis
by SET/TAF-Ib
To further elucidate the biological role of SET/TAF-Ib in
the cellular functions of p53, we performed an MTT assay
to measure cell viability. The results of the MTT assay
indicate that the strong cell death or apoptosis-inducing
activity of p53 was effectively abrogated by co-
transfection with SET/TAF-Ib in exogenous p53-
expressing H1299 (Figure 6A and Supplementary Figure
S6A). Again, the two sh-SET/TAF-Ib RNAs efﬁciently
downregulated the effects of SET/TAF-Ib on p53 and
further decreased cell survival (Figure 6A). BrdU incorp-
oration assay for measurement of cellular proliferation
indicated that the growth inhibitory activity of p53 was
impeded by overexpression of SET/TAF-Ib and restored
by sh-SET/TAF-Ib, supporting SET/TAF-Ib-mediated
regulation of p53 activity in both HCT116 and H1299
cells (Figure 6B and Supplementary Figure S6B).
Exogenous p53-expressing H1299 cells showed no indica-
tion of BrdU incorporation when SET/TAF-Ib was
overexpressed (Supplementary Figure S6B). FACS
analysis revealed that p53-dependent G1 arrest following
doxorubicin treatment was rescued by SET/TAF-Ib
expression but not by the two sh-SET/TAF-Ib RNAs
(Figure 6C). Consistent with the MTT assay results,
SET/TAF-Ib decreased the apoptotic cell population
(sub-G1) induced by p53 following doxorubicin treatment
(13–4%), and both sh-SET/TAF-Ib RNAs increased the
number of cells entering apoptosis from 4% to 13% and
Figure 5. Continued.
Nucleic AcidsResearch, 2012,Vol. 40,No. 1 83Figure 6. SET/TAF-Ib represses p53-mediated cell cycle arrest and apoptosis and induces proliferation. (A) Doxorubicin-treated H1299 cells were
transfected with the indicated constructs for MTT assay. Results are shown as means SD; n=3.**P<0.01 and ***P<0.001 compared with Day
0. (B) HCT116 cells were transfected with p53, SET/TAF-Ib, sh-CTL and sh-SET/TAF-Ib #1 or #2 as indicated upon doxorubicin treatment. At
72-h post-transfection, cells were ﬁxed and BrdU assays performed. Results are shown as means SD. n=3. **P<0.01 and ***P<0.001. (C)
FACS analysis of H1299 cells transfected with p53 alone or co-transfected with SET/TAF-Ib, SET/TAF-Ib3, sh-CTL and sh-SET/TAF-Ib #1 or
#2, followed by doxorubicin treatment. (D) H1299 cells transiently transfected with the indicated constructs upon doxorubicin treatment were
subjected to TUNEL assay. DNase I-treated cells were shown as a positive control. The numbers of TUNEL-positive cells are shown in the
numbers below the pictures.
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SET/TAF-Ib were conﬁrmed by sh-SET/TAF-Ib RNA #2
treatment, which increased the apoptotic cell population
up to 20% compared to that of doxorubicin-treated cells
with p53 (13%). Again, SET/TAF-Ib3 did not inﬂuence
either G1 arrest or apoptosis induced by doxorubicin.
Negative regulation of p53-mediated apoptosis by SET/
TAF-Ib was also investigated by TUNEL assay. The
apoptotic nuclei in DNase I-treated control and
p53+doxorubicin-treated cells were not found in SET/
TAF-Ib-expressing H1299 cells. However, the number of
dark brown-stained apoptotic cells increased upon expres-
sion of SET/TAF-Ib3 and both sh-SET/TAF-Ib RNAs,
which supports the negative regulation of p53-mediated
apoptosis by SET/TAF-Ib (Figure 6D).
SET/TAF-Ib inhibits UV-mediated apoptosis in
Drosophila
To further investigate the physiological signiﬁcance of
SET/TAF-Ib in acetylated p53-mediated apoptosis, we
used the developing Drosophila eye as an in vivo model
system. We examined the effect of Drosophila p53 (dp53)
and dSet overexpression using the eye-speciﬁc GMR-gal4
driver. The GMR driver induces target gene expression in
the posterior region of the eye disc. Similar to mammalian
p53, dp53 functions in the cellular response to stress, and
overexpression of dp53 in the ﬂy eye results in severe
apoptosis and a small eye phenotype (29–31). Consistent
with previous studies, expression of dp53 in the ﬂy eye
under direct control of the eye-speciﬁc GMR driver
(GMR>dp53) resulted in a signiﬁcant reduction in eye
size as well as disruption of the ommatidia structure
(Figure 7A). Next, we generated transgenic ﬂies
overexpressing both dp53 and dSet in the eye. The defect-
ive eye phenotype of GMR>dp53 was signiﬁcantly
rescued by co-expression of dSet, which suggests the
negative regulation of dp53-mediated apoptosis by SET/
TAF-Ib (Figure 7A). Next, we determined whether or not
dSet expression can suppress the expression of dp53-target
genes. In response to ionizing radiation, dp53 targets the
pro-apoptotic genes reaper and hid (30,32,33). Expression
of reaper and hid was markedly reduced by co-expression
of dSet, suggesting negative regulation of dp53-mediated
apoptosis by SET/TAF-Ib in the stress response pathway
(Figure 7B). To examine the effect of dSet on dp53 acetyl-
ation status, we ﬁrst immunoprecipitated dp53 using
antibodies and then conﬁrmed acetylation of dp53 using
anti-acetyl lysine antibodies. In accordance with the
SET/TAF-Ib-mediated inhibition of p53 acetylation in
this study, the acetylation level of dp53 was signiﬁcantly
reduced by co-expression of dp53 and dSet, suggesting
that SET/TAF-Ib has a signiﬁcant effect on pd53
(Figure 7C). To extend the effects of dSet under cellular
stress conditions, we examined the ﬂy eye phenotype
under UV irradiation. Compared with wild-type eye, ex-
pression of dSet alone only slightly disrupted the
arrangement of ommatidia (Figure 7D). Upon UV irradi-
ation during pupariation, the wild-type ﬂy eye showed
reduced size and a severe apoptotic phenotype
(Figure 7D). On the contrary, expression of dSet
produced a less severe apoptotic eye phenotype even in
the presence of UV irradiation (Figure 7D). The acetyl-
ation level of dp53 induced in UV-irradiated wild-type
ﬂy signiﬁcantly decreased upon expression of dSet
(Figure 7E). Taken together, these results suggest that
dSet inhibited acetylation of Drosophila dp53 and nega-
tively regulated dp53-mediated apoptosis under cellular
stress conditions.
DISCUSSION
The linkage between the acetylation of histone lysine
residues and transcriptional regulation has been well
established (34,35). Since then, a large number of
non-histone proteins have been found to be acetylated as
well.
p53 protein can be activated by cellular stresses such as
DNA damage, hypoxia or viral and cellular oncogenes.
Ever since the ﬁrst observation that non-histone protein
p53 is regulated by HAT-mediated acetylation, numerous
studies have been carried out to understand the
post-translational modiﬁcations of p53. The level of p53
acetylation is correlated with p53 activation and acetyl-
ation by different HATs, resulting in subtle differences
in the biological properties of p53.
In this study, we demonstrated that the proto-oncogene
protein SET/TAF-Ib inhibits p300- and PCAF-mediated
p53 acetylation and negatively regulates p53 activity. We
determined that the acidic INHAT domain of SET/
TAF-Ib located in the C-terminus is important for both
inhibition of acetylation and direct interaction with p53.
Moreover, stress-induced p53 acetylation was efﬁciently
inhibited by SET/TAF-Ib. We also observed that
knockdown of SET/TAF-Ib by different sh-RNAs signiﬁ-
cantly activates p53-mediated p21 transcription. In
addition, SET/TAF-Ib negatively regulates stress-induced
p53 activation by repressing the recruitment of p53 to
target promoters. By targeting p53 acetylation, SET/
TAF-Ib inhibits p53-mediated cell cycle arrest and apop-
tosis, which may result in cellular proliferation. In our
other results, the Drosophila dp53-induced apoptotic
phenotype was rescued by co-expression with dSet.
Drosophila dSet inhibited dp53 acetylation as well as ex-
pression of the apoptosis target genes reaper and hid.
Under stress conditions, dSet still inhibited dp53 acetyl-
ation. It has been reported that GMR driver-mediated
dp53 expression in the eye disc cannot completely
prevent cell death in response to whole ﬂy body UV ir-
radiation (36). Nonetheless, partial rescue of
UV-mediated apoptotic phenotype by dSet leaves open
the possibility of another apoptotic pathway besides
UV-induced dp53 acetylation-mediated cell death. SET/
TAF-Ib containing the INHAT complex is a group of
multifunctional proteins with acidic domains that are
involved in various nuclear and cytoplasmic signaling
pathways. Recent studies have indicated that INHAT
complex proteins are involved in the regulation of apop-
totic cell death, with SET/TAF-Ib as an inhibitor (17,18).
Since SET/TAF-Ib is an oncoprotein, its antiapoptotic
Nucleic AcidsResearch, 2012,Vol. 40,No. 1 85functions may contribute to the accumulation of damaged
cells under stress circumstances.
Negative regulation of p53 activity by NIR (novel
INHAT repressor) has been suggested as a regulatory
mechanism of p53 activity (22). In this study, we
expanded the role of INHAT regulator SET/TAF-Ib to
the important non-histone protein p53. We showed that
INHAT subunit SET/TAF-Ib plays a novel repressive role
in p53 activity due to the inhibition of p53 acetylation.
Considering that SET/TAF-Ib is frequently upregulated
in a number of cancers, we propose that SET/TAF-Ib
inhibits both p300- and PCAF-mediated p53 acetylation,
which leads to inhibition of cell cycle arrest or apoptosis
in the presence of different cellular stresses and
guides cellular proliferation toward carcinogenesis
(Figure 7F).
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eye-speciﬁc GMR-gal4 driver. Adult eyes from transgenic ﬂies were viewed by scanning electron microscopy (SEM). The eye phenotypes of wild-type
ﬂy (left), dp53-overexpresssing ﬂy (GMR>dp53, middle) and dp53- and dSet-overexpresssing ﬂy (GMR>dp53; dSet, right). (B) Eye-speciﬁc dp53 or
dSet overexpression along with expression of the dp53-target genes hid and reaper were conﬁrmed by RT–PCR. Equal loading of samples was
conﬁrmed using an rp49-speciﬁc primer. (C) Western blot analysis of the anti-dp53 immunoprecipitates from dp53- and dSet-overexpresssing ﬂies
with anti-acetyl lysine (top) and anti-dp53 antibodies (middle). Equal loading of samples was conﬁrmed using anti-b-actin antibody. (D)U V
irradiation-mediated apoptotic phenotypes. UV irradiation (40000mJ/cm
2) led to a change in eye morphology when applied during pupal develop-
ment. A non-irradiated adult eye (WT and GMR>dSet, left) and UV-irradiated adult eye (right) after 2h. (E) Western blot analysis of the anti-dp53
immunoprecipitates from dp53- and dSet-overexpresssing ﬂies and UV-irradiated ﬂies with anti-acetyl lysine (top) and anti-dp53 antibodies (middle).
Western blot images were quantitatively analyzed in the bar graph using the Image J program (right panels). (F) Model of the mechanism of SET/
TAF-Ib-mediated repression of p53 activity.
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